FDA/CDC

FDA clears first-of-its-kind phone app for insulin management


 

The Food and Drug Administration has granted 501(k) clearance to a phone app for managing insulin in patients with type 2 diabetes.

FDA icon

The app will enhance Hygieia’s d-Nav Insulin Guidance Service, which uses Cloud-based technology and a small group of health care professionals to support physicians and help patients with diabetes achieve better glycemic control by providing personalized insulin adjustments. The system has been shown, in a 90-day clinical study, to reduce both costs and levels of glycosylated hemoglobin. Patients can use the app to enter glucose-event data and receive a recommended insulin dose.

“Insulin therapy is critical to the health of more than 8 million people in the United States, but it is often ineffective, largely because it requires a continual, personalized adjustment that is not practical for physicians and not manageable for patients. The d-Nav service, including the user-friendly phone app, makes insulin therapy more effective, less time intensive, and less costly for everyone involved,” Eran Bashan, CEO of Hygieia, said in a press release.

This is the first insulin-mangement app that can titrate individualized doses for all insulin regimens and the first that can connect to any glucose meter that shares information with the cloud. It is available for both Android and iOS.

Find the full press release on the Hygieia website.

Recommended Reading

Lessons learned from the PCSK9 inhibitor trials
MDedge Family Medicine
(Sponsored) Video Roundtable: Basal Insulin Pharmacology
MDedge Family Medicine
Insulin may be toxic to the placenta in early pregnancy
MDedge Family Medicine
Roux-en-Y achieves diabetes remission in majority of patients
MDedge Family Medicine
SGLT2 inhibitors morph into HF drugs
MDedge Family Medicine
What comes first with SGLT2 inhibitors – diabetes or heart failure?
MDedge Family Medicine
Study Design, Population, and Key Outcomes of DECLARE-TIMI 58 Compared With Other Cardiovascular Outcomes Trials for Sodium-Glucose Cotransporter-2 Inhibitors
MDedge Family Medicine
FDA approves first interoperable insulin infusion pump
MDedge Family Medicine
Lower prices drive OTC insulin sales at Walmart
MDedge Family Medicine
AACE/ACE algorithm provides practical clinical guidance on managing diabetes
MDedge Family Medicine